One in two Australians will be diagnosed with cancer during their lifetime. Most anti-cancer drugs are cytotoxic with significant side effects, so new highly selective drugs with minimal toxicity are critically needed.
Studies at DDB investigate the tumour microenvironment as a novel therapeutic target. We study the peripheral nervous system and its capacity to regulate key tumour processes, including metastasis, inflammation, angiogenesis and hypoxia. We are also examining the cascade of fatty liver disease, inflammation and fibrosis in the progression to liver cancer.
We are evaluating drugs that interact with the peripheral nervous system as novel strategies to limit cancer progression, and working with medicinal chemists to design and evaluate new anti-cancer compounds.